<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144857</url>
  </required_header>
  <id_info>
    <org_study_id>213/19-6-12</org_study_id>
    <nct_id>NCT02144857</nct_id>
  </id_info>
  <brief_title>Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis</brief_title>
  <official_title>Effects of Treatment With Biological Agents on Endothelial Glycocalyx,Arterial Elastic Properties, Coronary Flow, Myocardial Deformation and Twisting in Psoriasis. Comparative Study With Patients With CAD or Untreated Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis has been associated with an increasing risk for atherosclerosis. The investigators&#xD;
      investigated whether surrogate markers of subclinical atherosclerosis, vascular dysfunction&#xD;
      and myocardial dysfunction are impaired in patients with psoriasis compared to normal&#xD;
      controls ,coronary artery disease patients and untreated hypertension subjects. The&#xD;
      investigators also examined the effect of treatment with biological vs no biological agents&#xD;
      on vascular and LV function in psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will compare patients with psoriasis with age and sex matched normal&#xD;
      controls as well as patients with angiographically documented CAD and patients with untreated&#xD;
      hypertension (HYP) used as positive control groups&#xD;
&#xD;
      Patients with psoriasis (PS) will be randomized to receive an anti-tumor necrosis-a (TNF-a)&#xD;
      ,an anti- interleukin 12/23 regimen, an interleukin 17A antagonist, apremilast (inhibitor of&#xD;
      phosphodiesterase-4) or a cyclosporine regimen.&#xD;
&#xD;
      The anti-TNF-agent, Etanercept will be given at a dose 50mg twice weekly for 12 weeks and&#xD;
      after then once weekly.&#xD;
&#xD;
      The anti-IL12/23 regimen, Ustekinumab will be given at a dose 45 mg at the first visit, at 4&#xD;
      weeks and every 12 weeks if body weight is up to 90 kgr. For body weight &gt;90kgr dose will be&#xD;
      adjusted accordingly.&#xD;
&#xD;
      The IL-17A antagonist regimen namely secukinumab 300 mg SC at weeks 0, 1, 2, 3, and 4 and 300&#xD;
      mg SC once monthly afterwards Apremilast will be given at a dose of 30mg orally twice daily&#xD;
      Cyclosporine will be administered at a dose 2.5-3mg/kgr daily.&#xD;
&#xD;
      At baseline , after 12 weeks and one year of treatment, the investigators will measure:&#xD;
&#xD;
        1. pulse wave velocity (PWVc) augmentation index (AI) central systolic blood pressure&#xD;
           (cSBP) (Complior, Alam Medical and Arteriograph,TensioMed)&#xD;
&#xD;
        2. flow-mediated dilation of the brachial artery (FMD)&#xD;
&#xD;
        3. carotid intima-media thickness (IMT) by ultrasonography&#xD;
&#xD;
        4. coronary flow reserve of the LAD (CFR) by Doppler echocardiography&#xD;
&#xD;
        5. E'/A of mitral annular velocities ,LV longitudinal (GLS -%),strain, and strain rate&#xD;
           (LongSr-l/s), peak twisting (Tw -deg),peak twisting (Tw-deg/sec)velocity,untwisting at&#xD;
           mitral valve opening (unTw) and untwisting (unTw) velocity using speckle tracking&#xD;
           echocardiography .&#xD;
&#xD;
        6. Perfused boundary region (PBR)of the sublingual arterial microvessels (ranged from 5-25&#xD;
           microns) using Sideview Darkfield imaging. (Microscan, Glycocheck) .The PBR in&#xD;
           microvessels is the cell-poor layer which results from the phase separation between the&#xD;
           flowing red blood cells (RBC) and plasma.The PBR includes the most luminal part of&#xD;
           glycocalyx that does allow cell penetration. Increased PBR is considered an accurate&#xD;
           index of reduced endothelial glycocalyx thickness because of a deeper RBC penetration in&#xD;
           the glycocalyx.&#xD;
&#xD;
        7. Fetuin serum levels, markers of oxidative stress such as malondialdehyde (MDA) serum&#xD;
           levels, protein carbonyls aw well as thrombosis and inflammation biomarkers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2014</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of effect (improvement or deterioration) of treatment with biological vs. non biological agents on endothelial function in psoriasis</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of effect (improvement or deterioration) of treatment with biological agents (anti-tumor necrosis factor-a, anti-interleukin 12/23, anti-interleukin 17A, or apremilast regimen) with the effects of cyclosporine on endothelial function as assessed by flow mediated dilatation of the brachial artery, coronary flow reserve and endothelial glycocalyx thickness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of effect (improvement or deterioration) of treatment with biological vs. non biological agents on vascular function in psoriasis</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of effect (improvement or deterioration) of treatment with biological agents (anti-tumor necrosis factor-a, anti-interleukin 12/23, anti-interleukin 17A, or apremilast regimen) with the effects of cyclosporine on vascular function as assessed by pulse wave velocity, augmentation index and central aortic blood pressure,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of effect (improvement or deterioration) of treatment with biological vs. non biological agents on cardiac function in psoriasis</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of effect (improvement or deterioration) of treatment with biological agents (anti-tumor necrosis factor-a, anti-interleukin 12/23 ,anti-interleukin 17A, or apremilast regimen) with the effects of cyclosporine on cardiac function as assessed by longitudinal myocardial deformation, twisting and untwisting of the left ventricle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences and similarities in endothelial function between psoriasis and control groups</measure>
    <time_frame>0 and 12 weeks</time_frame>
    <description>Differences in endothelial function between psoriasis and normal controls, and similarities in endothelial function between psoriasis and coronary artery disease patients and untreated hypertension patients before and after 4 week of anti-inflammatory treatment in patients with psoriasis .The following parameters will be compared among the study subgroups endothelial function as assessed by flow mediated dilatation of the brachial artery, coronary flow reserve and endothelial glycocalyx thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences and similarities in vascular function between psoriasis and control groups</measure>
    <time_frame>0 and 12 weeks</time_frame>
    <description>Differences in vascular function between psoriasis and normal controls, and similarities in vascular function between psoriasis and coronary artery disease patients and untreated hypertension patients before and after 4 week of anti-inflammatory treatment in patients with psoriasis .The following parameters will be compared among the study subgroups vascular function as assessed by pulse wave velocity, augmentation index and central aortic blood pressure,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences and similarities in cardiac function between psoriasis and control groups</measure>
    <time_frame>0 and 12 weeks</time_frame>
    <description>Differences in cardiac function between psoriasis and normal controls, and similarities in cardiac function between psoriasis and coronary artery disease patients and untreated hypertension patients before and after 4 week of anti-inflammatory treatment in patients with psoriasis The following parameters will be compared among the study subgroups cardiac function as assessed by longitudinal myocardial deformation, twisting and untwisting of the left ventricle</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Anti-TNFa regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etanercept 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti IL12/23 regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ustekinumab 45 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine 2.5-3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anti-interleukin 17 A regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>secukinumab 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inhibitor of phosphodiesterase-4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apremilast 30mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>50 mg</description>
    <arm_group_label>Anti-TNFa regimen</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ustekinumab</intervention_name>
    <description>45 mg</description>
    <arm_group_label>Anti IL12/23 regimen</arm_group_label>
    <other_name>Stelara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Cyclosporine 2.5-3 mg/kgr</description>
    <arm_group_label>Cyclosporine regimen</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>300 mg</description>
    <arm_group_label>anti-interleukin 17 A regimen</arm_group_label>
    <other_name>Cosentyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>30mg</description>
    <arm_group_label>inhibitor of phosphodiesterase-4</arm_group_label>
    <other_name>Otezla</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with psoriasis&#xD;
&#xD;
          -  Age and sex matched patients with CAD, with untreated hypertension and healthy&#xD;
             subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  for psoriasis patients were presence of wall motion abnormalities and ejection&#xD;
             fraction ≤ 50%, psoriatic arthritis, history of acute coronary syndrome, familial&#xD;
             hyperlipidemia, insulin dependent-diabetes mellitus, chronic obstructive pulmonary&#xD;
             disease or asthma, moderate or severe valvular heart disease, primary cardiomyopathies&#xD;
             and malignant tumors. CAD was excluded in psoriasis patients by absence of clinical&#xD;
             history, angina and reversible myocardial ischemia, as assessed by dobutamine stress&#xD;
             echocardiography or thallium scintigraphy&#xD;
&#xD;
          -  regarding the group of CAD patients, we only included patients without history of ST&#xD;
             elevation myocardial infarction in order to exclude the presence of transmural scar&#xD;
             compromising myocardial function indices. Thus, CAD patients with wall motion&#xD;
             abnormalities and ejection fraction of ≤ 50% were excluded. In addition, exclusion&#xD;
             criteria, were history of acute coronary syndrome without ST-segment elevation within&#xD;
             the last year, familial hyperlipidemia, insulin dependent-diabetes mellitus, chronic&#xD;
             obstructive pulmonary disease or asthma, moderate or severe valvular heart disease,&#xD;
             primary cardiomyopathies and malignant tumor&#xD;
&#xD;
          -  in normal controls, CAD was excluded by the presence of normal ECG, absence of&#xD;
             clinical history and absence of reversible ischemia by means of treadmill test or&#xD;
             dobutamine stress echocardiography&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignatios Ikonomidis, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignatios Ikonomidis, Dr</last_name>
    <phone>2105831264</phone>
    <email>ignoik@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Varoudi, Dr</last_name>
    <phone>6909001116</phone>
    <email>mvaroudi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Attikon Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignatios Ikonomidis, Dr</last_name>
      <phone>+302105832187</phone>
      <email>ignoik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignatios Ikonomidis, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Ignatios Ikonomidis</investigator_full_name>
    <investigator_title>Assistant Professor in Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Apremilast</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

